A Phase II Efficacy and Safety Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
Condition: Myelodysplastic Syndromes Interventions: Drug: MBG453; Drug: Placebo; Drug: Hypomethylating agents Sponsor: Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials